1. Home
  2. News
  3. Dimerix Limited
  4. New Clinical Trial for DMX-200 in Diabetic Kidney Disease
More Dimerix Limited news
Dimerix LimitedASX: DXB

New Clinical Trial for DMX-200 in Diabetic Kidney Disease

Jun 6, 2022 at 11:19 PM EDT · Issued by Dimerix Limited

Filed with ASX · Jun 6, 2022 at 11:19 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/new-clinical-trial-for-dmx-200-in-diabetic-kidney-disease

Dimerix Limited on 6ix

Story so far

  • Dimerix Plans for Next Study in Diabetic Kidney DiseaseJan 28, 2021
  • DMX-200 Clinical Trial UpdateJan 7, 2020
  • DMX-200 Phase 2 Clinical Trial in FSGS Fully RecruitedJul 10, 2019

Earlier from Dimerix

  • Phase 3 FSGS Kidney Trial First Patient RecruitedMay 30, 2022
  • Dimerix presentation at Bioshares Biotech SummitMay 11, 2022
  • FDA IND Approval for Phase 3 Study of DMX-200 in FSGSMay 8, 2022
  • Dimerix Receives A$3.7M R&D Tax Incentive RebateMar 28, 2022
  • DSMB Change to REMAP-CAP COVID-19 StudyFeb 27, 2022

Later from Dimerix

  • REMAP-CAP COVID-19 Study Analysis UpdateJun 26, 2022
  • DMX-700 Study Shows Significant 80% Reduction in Lung InjuryJul 3, 2022
  • New Patent Family Application for DMX-700Aug 8, 2022
  • CLARITY 2.0 COVID-19 Study Concludes RecruitmentAug 17, 2022
  • Appendix 4E and 2022 Annual ReportAug 28, 2022
All Dimerix news releases↗

Follow Dimerix into a list and get an email when it puts out news.

Follow Dimerix
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer